IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 329 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,022,772 | +0.1% | 309,144 | -9.5% | 0.01% | 0.0% |
| Q2 2023 | $14,009,735 | +124797.3% | 341,451 | +8.8% | 0.01% | +25.0% |
| Q1 2023 | $11,217 | -8.1% | 313,865 | -2.9% | 0.00% | -20.0% |
| Q4 2022 | $12,206 | -99.9% | 323,178 | -4.7% | 0.01% | -16.7% |
| Q3 2022 | $15,007,000 | +16.3% | 339,284 | -2.7% | 0.01% | +20.0% |
| Q2 2022 | $12,908,000 | +17.0% | 348,686 | +10.4% | 0.01% | +25.0% |
| Q1 2022 | $11,028,000 | +3.1% | 315,819 | -10.1% | 0.00% | +33.3% |
| Q4 2021 | $10,696,000 | -49.3% | 351,476 | -44.1% | 0.00% | -50.0% |
| Q3 2021 | $21,079,000 | -26.9% | 628,476 | -13.1% | 0.01% | -33.3% |
| Q2 2021 | $28,844,000 | -32.4% | 723,101 | -23.8% | 0.01% | -35.7% |
| Q1 2021 | $42,678,000 | +22.1% | 949,237 | +53.5% | 0.01% | +16.7% |
| Q4 2020 | $34,965,000 | +72.6% | 618,411 | +44.9% | 0.01% | +50.0% |
| Q3 2020 | $20,256,000 | -28.2% | 426,898 | -10.7% | 0.01% | -27.3% |
| Q2 2020 | $28,200,000 | +25.0% | 478,301 | +0.2% | 0.01% | 0.0% |
| Q1 2020 | $22,564,000 | -21.7% | 477,227 | +0.0% | 0.01% | 0.0% |
| Q4 2019 | $28,826,000 | -3.6% | 477,159 | -4.4% | 0.01% | -8.3% |
| Q3 2019 | $29,907,000 | -3.6% | 499,187 | +3.4% | 0.01% | 0.0% |
| Q2 2019 | $31,037,000 | +2991.3% | 482,909 | +3803.9% | 0.01% | +140.0% |
| Q1 2019 | $1,004,000 | +60.6% | 12,370 | +6.9% | 0.01% | +25.0% |
| Q4 2018 | $625,000 | +34.4% | 11,570 | +3.7% | 0.00% | +33.3% |
| Q2 2018 | $465,000 | -5.5% | 11,153 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $492,000 | -70.5% | 11,153 | -66.4% | 0.00% | -72.7% |
| Q4 2017 | $1,668,000 | -32.7% | 33,153 | -32.1% | 0.01% | -31.2% |
| Q3 2017 | $2,477,000 | -30.1% | 48,853 | -29.9% | 0.02% | -30.4% |
| Q2 2017 | $3,543,000 | +23.4% | 69,653 | -2.5% | 0.02% | +35.3% |
| Q1 2017 | $2,872,000 | +160.6% | 71,433 | +210.1% | 0.02% | +183.3% |
| Q4 2016 | $1,102,000 | +30.6% | 23,033 | 0.0% | 0.01% | +20.0% |
| Q3 2016 | $844,000 | +57.5% | 23,033 | 0.0% | 0.01% | +66.7% |
| Q2 2016 | $536,000 | -42.6% | 23,033 | 0.0% | 0.00% | -40.0% |
| Q1 2016 | $933,000 | +44.2% | 23,033 | +120.4% | 0.01% | +66.7% |
| Q4 2015 | $647,000 | – | 10,452 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |